<?xml version='1.0' encoding='utf-8'?>
<document id="28542081"><sentence text="Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception."><entity charOffset="14-24" id="DDI-PubMed.28542081.s1.e0" text="Dapivirine" /></sentence><sentence text="To evaluate the potential for a clinically relevant drug-drug interaction with concomitant use of a dapivirine vaginal ring, a novel antiretroviral-based HIV-1 prevention strategy, and hormonal contraception by examining contraceptive efficacies with and without dapivirine ring use"><entity charOffset="100-110" id="DDI-PubMed.28542081.s2.e0" text="dapivirine" /><entity charOffset="263-273" id="DDI-PubMed.28542081.s2.e1" text="dapivirine" /><pair ddi="false" e1="DDI-PubMed.28542081.s2.e0" e2="DDI-PubMed.28542081.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28542081.s2.e0" e2="DDI-PubMed.28542081.s2.e1" /></sentence><sentence text="" /><sentence text="A secondary analysis of women participating in MTN-020/ASPIRE, a randomized, double-blind, placebo-controlled trial of the dapivirine vaginal ring for HIV-1 prevention"><entity charOffset="123-133" id="DDI-PubMed.28542081.s4.e0" text="dapivirine" /></sentence><sentence text="" /><sentence text="Use of a highly effective method of contraception was an eligibility criterion for study participation" /><sentence text=" Urine pregnancy tests were performed monthly" /><sentence text=" Pregnancy incidence by arm was calculated separately for each hormonal contraceptive method and compared using an Andersen-Gill proportional hazards model stratified by site and censored at HIV-1 infection" /><sentence text="" /><sentence text="Of 2629 women enrolled, 2310 women returned for follow-up and reported using a hormonal contraceptive method at any point during study participation (1139 in the dapivirine arm and 1171 in the placebo arm)"><entity charOffset="162-172" id="DDI-PubMed.28542081.s10.e0" text="dapivirine" /></sentence><sentence text=" Pregnancy incidence in the dapivirine arm versus placebo among women using injectable depot medroxyprogesterone acetate was 0"><entity charOffset="28-38" id="DDI-PubMed.28542081.s11.e0" text="dapivirine" /><entity charOffset="93-120" id="DDI-PubMed.28542081.s11.e1" text="medroxyprogesterone acetate" /><pair ddi="false" e1="DDI-PubMed.28542081.s11.e0" e2="DDI-PubMed.28542081.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28542081.s11.e0" e2="DDI-PubMed.28542081.s11.e1" /></sentence><sentence text="43% vs" /><sentence text=" 0" /><sentence text="54%, among women using injectable norethisterone enanthate was 1"><entity charOffset="34-58" id="DDI-PubMed.28542081.s14.e0" text="norethisterone enanthate" /></sentence><sentence text="15% vs" /><sentence text=" 0%, among women using hormonal implants was 0" /><sentence text="22% vs" /><sentence text=" 0" /><sentence text="69%, and among women using oral contraceptive pills was 32" /><sentence text="26% vs" /><sentence text=" 28" /><sentence text="01%" /><sentence text=" Pregnancy incidence did not differ by study arm for any of the hormonal contraceptive methods" /><sentence text="" /><sentence text="Use of the dapivirine ring does not reduce the effectiveness of hormonal contraceptives for pregnancy prevention"><entity charOffset="11-21" id="DDI-PubMed.28542081.s25.e0" text="dapivirine" /></sentence><sentence text=" Oral contraceptive pill use was associated with high pregnancy incidence, potentially because of poor pill adherence" /><sentence text=" Injectable and implantable methods were highly effective in preventing pregnancy" /><sentence text="" /></document>